rcc: following patients on immunotherapy vs tki therapy
Published 7 years ago • 319 plays • Length 6:38Download video MP4
Download video MP3
Similar videos
-
9:52
factors in selecting immunotherapy or tki inhibition
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc
-
7:18
vegf tki therapy in the adjuvant setting of rcc
-
1:35
dr. grigg on immunotherapy/tki combinations in rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
0:59
dr. alva on tki monotherapy and combinations for rcc
-
5:11
selecting immunotherapy versus vegf tki for mrcc
-
1:02
dr. sznol on immunotherapy in patients with rcc
-
55:12
selecting and sequencing targeted and immunotherapy regimens for patients with rcc
-
1:52
dr. powles on monitoring immunotherapy effects in patients with rcc
-
1:44
dr. figlin discusses sequencing mtor inhibitors and tkis in rcc
-
1:54
dr. figlin on tki therapy options in renal cell carcinoma
-
2:29
dr. ornstein on challenges with immunotherapy in rcc
-
6:36
choosing post-progression therapy for metastatic rcc
-
0:53
immunotherapy combination strategies in rcc
-
1:32
dr. figlin on promise of immunotherapy plus tki combinations in rcc
-
1:50
dr. gong on adverse events of tki vegf-directed therapy in rcc
-
9:10
utilizing tkis in oligometastatic rcc
-
4:28
prognostic factors and treatment selection in rcc